Gilead Sciences

Live  

Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.

Gilead Sciences is a company that focuses on making medicines, especially for serious diseases like HIV, liver problems, and some types of cancer. Imagine Gilead as a superhero that creates special potions to help people feel better and live healthier lives.
The way Gilead makes money is by creating these medicines and then selling them to hospitals and pharmacies. Doctors use these medicines to help patients get better, and the hospitals pay Gilead for the drugs. Sometimes, they also work with big research groups to discover new medicines, and this can bring in even more money.
Gilead is successful for a few reasons. First, they invest a lot of time and money into research to find new treatments. This means they’re always trying to create better and more effective medicines. Second, they have strong patents, which are like protective shields that keep other companies from copying their drugs for a certain number of years. This helps them sell their medicines without much competition. Lastly, as more people around the world need healthcare and better treatments, Gilead is well-positioned to help them, which means they will likely continue to be successful in the future.
In summary, Gilead Sciences is good at making medicines that help fight big illnesses, they know how to make money by selling those medicines, and they have the skills and plans to remain a strong player in the healthcare industry for years to come.

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==

AI does pose potential threats to Gilead Sciences, primarily through substitution, disintermediation, and margin pressure, but the extent of these threats is influenced by various factors specific to the pharmaceutical industry.
1. Substitution: AI technologies are advancing rapidly, particularly in drug discovery and development. Machine learning algorithms can analyze vast datasets to identify new drug candidates, which could lead to the development of competing therapies that may replace existing Gilead products. Additionally, AI-driven personalized medicine approaches could tailor treatments more effectively than Gilead’s current offerings, potentially eroding market share if Gilead does not adapt.
2. Disintermediation: AI could change the traditional pharmaceutical supply chain and patient care models. For instance, AI-enabled platforms could facilitate direct connections between drug developers and patients, bypassing traditional distribution channels. This shift could challenge Gilead’s ability to reach customers effectively, reducing the role of established intermediaries like pharmacies and distributors.
3. Margin Pressure: The implementation of AI in healthcare often aims to increase efficiency and reduce costs. If competitors leverage AI to streamline their operations or reduce the costs associated with R&D, they might be able to offer products at lower prices or with higher margins. Gilead may face pressure to lower its own prices or invest in new AI technologies to maintain a competitive position, which can affect profit margins.
Overall, while AI presents various risks to Gilead Sciences, the company’s response, including its investment in AI technologies and its ability to innovate, will play a crucial role in determining the actual impact of these threats on its products, services, and competitive positioning.

Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmiBZb3Vy IGZyZWUgY2 9weSBvZiA8 aT4iVGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrcyI8L2 k+IGlzIHdh aXRpbmcKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdSMm xzWlcgRmtJ Rk5qYVdWdS BZMlZ6SUhk aGN5IEJtYj NWdVpHVmsg SUdsdUlERT VPRCBjZ1lu a2dUV2xqIG FHRmxiQ0JT YVcgOXlaR0 Z1TENCaCBJ RzFsWkdsal lXIHdnWkc5 amRHOXkgSU daeWIyMGdU bSBWM0lGbH ZjbXN1IElG Um9aU0JqYj IgMXdZVzU1 SUhkaCBjeU J1WVcxbFpD IEJoWm5SbG NpQjAgYUdV Z1ltbGliRy BsallXd2di R0Z1IFpDQn ZaaUJIYVcg eGxZV1FzSU hkbyBhV05v SUhkaGN5IE JyYm05M2Jp Qm0gYjNJZ2 FYUnpJRyBo bFlXeHBibW NnIGNISnZj R1Z5ZEcgbG xjeTQ4WW5J KyBNaTRnUj Jsc1pXIEZr SUZOamFXVn UgWTJWeklH bHpJRyBFZ1 ltbHZjR2ho IGNtMWhZMl YxZEcgbGpZ V3dnWTI5dC BjR0Z1ZVNC MGFHIEYwSU dadlkzVnog WlhNZ2IyNG daRyBWMlpX eHZjR2x1IF p5QmhibVFn WTIgOXRiV1 Z5WTJsaCBi R2w2YVc1bk lIIFJvWlhK aGNHbGwgY3 lCbWIzSWdi RyBsbVpTMT BhSEpsIFlY UmxibWx1Wn kgQmthWE5s WVhObCBjeX dnZDJsMGFD IEJoSUhCaG NuUnAgWTNW c1lYSWdabS A5amRYTWdi MjRnIFNFbF dMMEZKUkYg TXNJR2hsY0 dGMCBhWFJw Y3lCQ0lHIE Z1WkNCRExD QnMgYVhabG NpQmthWCBO bFlYTmxjeX dnIGIyNWpi Mnh2WjMga3 NJR0Z1WkNC eSBaWE53YV hKaGRHIDl5 ZVNCa2FYTm wgWVhObGN5 NDhZbiBJK0 15NGdWR2hs IElHTnZiWE JoYm4gbmln Smx6SUdacC Bjbk4wSUcx aGFtIDl5SU dKeVpXRnIg ZEdoeWIzVm 5hQyBCallX MWxJR2x1IE lERTVPVFln ZDIgbDBhQ0 IwYUdVZyBZ WEJ3Y205Ml lXIHdnYjJZ Z2RHaGwgYV hJZ1NFbFdJ SCBSeVpXRj BiV1Z1IGRD QmtjblZuTE MgQldhWEps WVdRcyBJSG RvYVdOb0lI IGRoY3lCMG FHVWcgWm1s eWMzUWdkSC BKbFlYUnRa VzUwIElIUn ZJSFJoY20g ZGxkQ0JoYm lCbCBibnA1 YldVZ1kyIE ZzYkdWa0lI SmwgZG1WeW MyVWdkSCBK aGJuTmpjbW x3IGRHRnpa U0IwYUcgRj BJR2x6SUdW eiBjMlZ1ZE dsaGJDIEJt YjNJZ2RHaG wgSUhKbGNH eHBZMiBGMG FXOXVJRzlt IElIUm9aU0 JJU1YgWWdk bWx5ZFhNdS BQR0p5UGpR dUlFIGx1SU RJd01URXMg SUVkcGJHVm haQyBCVFky bGxibU5sIG N5QmhZM0Yx YVggSmxaQ0 IwYUdVZyBZ bWx2Y0doaG NtIDFoWTJW MWRHbGogWV d3Z1kyOXRj RyBGdWVTd2 dVR2hoIGNt MWhjM05sZE Mgd2dabTl5 SUNReCBNU0 JpYVd4c2FX IDl1TGlCVW FHbHogSUdG amNYVnBjMi BsMGFXOXVJ R0p5IGIzVm 5hSFFnUjIg bHNaV0ZrSU hSbyBaU0Jp Ykc5amEyIE oxYzNSbGNp QmsgY25Wbk xDQlRiMyBa aGJHUnBMQ0 IzIGFHbGph Q0J5WlggWn ZiSFYwYVc5 dSBhWHBsWk NCMGFHIFVn ZEhKbFlYUn QgWlc1MElH WnZjaSBCb1 pYQmhkR2ww IGFYTWdReT Q4WW4gSStO UzRnUjJscy BaV0ZrSUZO amFXIFZ1WT JWeklHaGgg Y3lCaElITj BjbSA5dVp5 QmpiMjF0IG FYUnRaVzUw SUggUnZJR0 52Y25CdiBj bUYwWlNCem IyIE5wWVd3 Z2NtVnogY0 c5dWMybGlh VyB4cGRIa3 VJRlJvIFpT QmpiMjF3WV cgNTVJR2ho Y3lCayBaWF psYkc5d1pX IFFnWVc0Z1 lXTmogWlhO eklIQnliMi BkeVlXMGdk RzhnIGNISn ZkbWxrWlMg QnBkSE1nYl dWayBhV05o ZEdsdmJuIE 1nZEc4Z2JH OTMgTFdsdV kyOXRaUyBC amIzVnVkSE pwIFpYTWdZ WFFnWkcgbH pZMjkxYm5S bCBaQ0J3Y2 1salpYIE1z SUdGdVpDQm ggYkhOdklH aGhjeSBCd2 NtOW5jbUZ0 IGN5QjBieU J6ZFggQndi M0owSUdOdi BiVzExYm1s MGVTIEJoYm 1RZ1pXUjEg WTJGMGFXOX VZVyB3Z2FX NXBkR2xoIG RHbDJaWE11 UEcgSnlQal l1SUVsdSBJ REl3TWpBc0 lFIGRwYkdW aFpDQlQgWT JsbGJtTmxj eSBCdFlXUm xJR2hsIFlX UnNhVzVsY3 kgQjNhWFJv SUdsMCBjeU JsZUhCbGNt IGx0Wlc1MF lXd2cgWkhK MVp5d2djbS BWdFpHVnph WFpwIGNpd2 dkMmhwWTIg Z2djMmh2ZD JWayBJSEJ5 YjIxcGMyIG x1WnlCeVpY TjEgYkhSek lHbHVJSCBS eVpXRjBhVz VuIElFTlBW a2xFTFQgRT VJSEJoZEds bCBiblJ6TG lCVWFHIFVn WkhKMVp5Qn kgWldObGFY WmxaQyBCbG JXVnlaMlZ1 IFkza2dkWE 5sSUcgRjFk R2h2Y21sNi BZWFJwYjI0 Z1puIEp2Yl NCMGFHVWcg UmtSQklHRn VaQyBCb1lY TWdjMmx1IF kyVWdZbVZs YmkgQmthWE 4wY21saSBk WFJsWkNCaG NtIDkxYm1R Z2RHaGwgSU hkdmNteGtM aiB4aWNqND NMaUJIIGFX eGxZV1FnVT IgTnBaVzVq WlhNZyBhR0 Z6SUdFZ1pH IGwyWlhKel pTQjMgYjNK clptOXlZMi BVc0lIZHBk R2dnIFpXMX diRzk1Wlcg VnpJR1p5Yj IwZyBiM1ps Y2lBMk5TIE JqYjNWdWRI SnAgWlhNZ1 lXNWtJRyBF Z2JHVmhaR1 Z5IGMyaHBj Q0IwWlcgRn RJRzFoWkdV ZyBkWEFnYj JZZ05EIGNs SUhkdmJXVn UgTGp4aWNq NDRMaSBCVW FHVWdZMjl0 IGNHRnVlU0 JvWVggTWdZ U0J6ZEhKdi BibWNnWjJ4 dlltIEZzSU hCeVpYTmwg Ym1ObExDQj NhWCBSb0lH OXdaWEpoIG RHbHZibk1n YVcgNGdUbT l5ZEdnZyBR VzFsY21sal lTIHdnUlhW eWIzQmwgTE NCS1lYQmhi aSB3Z1lXNW tJRUZ6IGFX RWdVR0ZqYV cgWnBZeTQ4 WW5JKyBPUz RnUjJsc1pX IEZrSUZOam FXVnUgWTJW eklHaGhjeS BCaVpXVnVJ RzVoIGJXVm tJRzl1WlMg QnZaaUIwYU dVZyBWMjl5 YkdUaWdKIG x6SUUxdmMz UWcgUVdSdG FYSmxaQyBC RGIyMXdZVz VwIFpYTWdZ bmtnUm0gOX lkSFZ1WlNC TiBZV2RoZW 1sdVpTIEJt YjNJZ1ptOT EgY2lCamIy NXpaVyBOMW RHbDJaU0I1 IFpXRnljeU FvTWogQXhO eTB5TURJdy BLUzQ4WW5J K01UIEF1SU VkcGJHVmgg WkNCVFkybG xibSBObGN5 QnBjeUJqIG IyMXRhWFIw WlcgUWdkRz hnYzNWeiBk R0ZwYm1GaW FXIHhwZEhr Z1lXNWsgSU doaGN5Qnpa WCBRZ2RHRn laMlYwIGN5 QjBieUJ5Wl cgUjFZMlVn ZEdobCBhWE lnWlc1MmFY IEp2Ym0xbG JuUmggYkNC cGJYQmhZMy BRc0lHbHVZ MngxIFpHbH VaeUJoSUcg ZHZZV3dnZE c4ZyBjMjkx Y21ObElEIE V3TUNVZ2Nt VnUgWlhkaF lteGxJRyBW c1pXTjBjbW xqIGFYUjVJ R0o1SUQgSX dNakFnWVc1 ayBJSEpsWk hWalpTIEJu Y21WbGJtaH YgZFhObElH ZGhjeSBCbG JXbHpjMmx2 IGJuTWdZbm tnTWogVWxJ R0o1SURJdy BNakl1CiAg ICAgICAgPC 9zcGFuPgog ICAgICAgIA ogICAgICAg IA==